2024

Rice

<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noreferrer noopener" class="deco-link">website policy</a>&nbsp;prior to making financial decisions.
</div> 
<p class="has-drop-cap">Elevance Health, Inc. (NYSE: ELV) has reported its financial results for the <a aria-label="first quarter of 2024 (opens in a new tab)" href="https://www.elevancehealth.com/content/dam/elevance-health/documents/earnings/1Q2024_ELV_Earnings_Release.pdf" target="_blank" rel="noreferrer noopener nofollow" class="deco-link">first quarter of 2024</a>, showcasing disciplined execution and strategic advancements in the healthcare industry. The company’s operating revenue for the quarter was $42.3 billion, a 0.9% increase from the first quarter of 2023.</p> 
<p>This growth was primarily driven by higher premium yields aligned with medical cost trends and development in Carelon, including a full quarter of revenue from BioPlus, which was acquired in February 2023. However, this growth was partially offset by attrition in Medicaid membership.</p> 
<p>Additionally, the company saw a 15.5% increase in diluted EPS to $9.59 and a 12.5% increase in adjusted diluted EPS to $10.64, reflecting strong financial performance and operational efficiency.</p> 
<h3 id="elevance-health-beats-eps-expectations-in-q1-misses-on-revenue">Elevance Health Beats EPS Expectations in Q1, Misses on Revenue</h3> 
<p>Elevance Health’s performance in the first quarter of 2024 has exceeded expectations in some areas while narrowly missing others. Analysts had projected an <a href="https://tokenist.com/investing/how-to-value-a-stock/" rel="dofollow" class="deco-link">EPS</a> of $10.48 and revenue of $42.47 billion for the quarter. The actual EPS of $10.64 surpassed expectations, demonstrating the company’s ability to generate profit beyond what was anticipated.</p> 
<p>However, revenue of $42.3 billion fell slightly short of the forecast, indicating a minor deviation in growth projections. Despite this, the company’s overall financial health remains robust, with significant improvements in operating gain and margin compared to the previous year.</p> 
<p>The operating gain for the quarter was $3.0 billion, up from $2.8 billion in 1Q 2023, and the operating margin improved to 7.1% from 6.8% in the same period.</p> 
<div class="cta-referral"> 
 <img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" class="cta-referral__img" loading="lazy" decoding="async"> 
 <div class="cta-referral__text"> 
  <p>Join our&nbsp;<a href="https://t.me/thetokenist" target="_blank" rel="noreferrer noopener nofollow" class="deco-link">Telegram group&nbsp;and never miss a breaking story.</a></p> 
 </div> 
</div> 
<h3 id="elevance-health-raises-guidance-for-2024-expects-net-income-per-diluted-share-to-be-over-34-05">Elevance Health Raises Guidance for 2024, Expects Net Income Per Diluted Share to Be Over $34.05 </h3> 
<p>Looking ahead, Elevance Health has raised its guidance for 2024, now expecting net income per diluted share to be greater than $34.05 and adjusted diluted net income per share to be greater than $37.20.</p> 
<p>This optimistic outlook is supported by the company’s strategic initiatives, including a significant partnership with Clayton, Dubilier &amp; Rice to advance primary care and physician enablement. This partnership is expected to accelerate innovation in care delivery, enhance healthcare experiences, and improve health outcomes, further advancing Elevance Health’s value-based care and physician enablement strategy.</p> <iframe src="https://tokenist.substack.com/embed" width="100%" height="320" style="border:1px solid #EEE; background:white;" frameborder="0" scrolling="no"></iframe> 
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em></p> 
<h3 id="br"><br></h3> 
<p>The post <a rel="nofollow" href="https://tokenist.com/elevance-health-inc-elv-surpasses-eps-expectations-at-10-64-in-q1/">Elevance Health (ELV) Beats EPS Expectations at $10.64 in Q1, Revenue Miss</a> appeared first on <a rel="nofollow" href="https://tokenist.com">Tokenist</a>.</p>

Elevance Health (ELV) Beats EPS Expectations at $10.64 in Q1, Revenue Miss

Table of Contents

Tokenist

Other articles published on Apr 18, 2024

Arkansas State House passes bills to limit cryptocurrency mining

Binance Enhances Stability by Shifting SAFU Reserve to USDC

Best 3 Cryptos That Are Your Golden Ticket to Prosperity

"When Should We Buy Bitcoin and When Should We Sell?" Popular Analyst PlanB Answered, Announced 2...

Shiba Inu Open Interest Explodes On Top Exchanges – Is This The Comeback?

Bitcoin Minetrix Offers Last Chance To Buy As $13 Million ICO Ends April 25

Join our free newsletter for daily crypto updates!